Rupatadine Patch Acrylic Adhesive Transdermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a rupatadine-containing external patch that can provide effective transdermal absorption with improved bioavailability and stable long-term administration, as existing oral forms face challenges such as decreased bioavailability due to the first-pass effect and sedative side effects associated with second-generation antihistamines.
Innovation Solution
A rupatadine-containing external patch using an acrylic adhesive base, combined with a solubilizer, softener, and surfactant, specifically incorporating organic acids, fatty acid esters, and polyoxyethylene compounds to enhance skin permeability and adhesion, thereby improving transdermal absorption and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of rupatadine is used, then the drug can be easily administered, but the bioavailability decreases due to the first pass effect by the liver
Solution Approach 1:
The patent introduces the skin as an intermediary absorption route instead of oral gastrointestinal absorption. By using a patch formulation, the drug bypasses the liver's first pass effect and enters systemic circulation directly through the bloodstream, thereby improving bioavailability while maintaining ease of administration.
2Ease of operation
If oral administration of second-generation antihistamines is used, then the drug can be easily administered, but sedative side effects such as drowsiness occur
Solution Approach 1:
The patent uses transdermal absorption as an intermediary route to deliver the drug directly into the bloodstream, bypassing gastrointestinal metabolism. This approach maintains the therapeutic effects of rupatadine while reducing sedative side effects, as the drug is absorbed more controllably through the skin rather than through oral ingestion.
3Reliability
If a patch formulation is developed for rupatadine, then the first pass effect can be avoided and bioavailability improved, but the formulation has not been investigated so far presenting development challenges
Solution Approach 1:
The patent optimizes the patch formulation by adjusting key parameters including using acrylic adhesive as the adhesive base, adding solubilizers (3-20% by weight), softeners (5-25% by weight), and surfactants (3-10% by weight). These parameter optimizations ensure adequate drug solubility, adhesive performance, and transdermal penetration while overcoming the lack of prior investigation into rupatadine patch formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch achieves excellent adhesion and transdermal absorption of rupatadine, offering a significant clinical effect with improved bioavailability and sustained drug release, surpassing other adhesive bases in skin permeability and stability.
Implementation Method 1
an external patch containing rupatadine characterized by using an acrylic adhesive as an adhesive base
Implementation Method 2
further comprising a solubilizer, a softener, and a surfactant
Implementation Method 3
further comprising a solubilizer, a softener, and a surfactant
Data Source
AI summary
An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.